Can NAD⁺ ingredients slow aging?

Anti-aging has been the hottest field in the life sciences over the past decade, and NAD⁺ (nicotinamide adenine dinucleotide) and its precursors NMN, NMNH, and NADH are undoubtedly at the forefront of public opinion.

 

Can oral NAD⁺ supplements truly reverse aging in the human body?

 

Animal studies have shown "rejuvenation," while human clinical trials have shown "slight rejuvenation." If NAD⁺ is compared to "currency," oral precursors are equivalent to "printing money." However, whether this money is accurately invested in "projects" such as mitochondria and DNA repair enzymes depends on multiple variables, including age, genetics, gut microbiome, and lifestyle. Therefore, the industry consensus is that NAD⁺ bulk powder enhancers are more suitable as interventions for "healthy aging" rather than as "elixirs of immortality."

 

1. Animal Experiments: Data So Beautiful It's "Outrageous"
A study just published in Nature Metabolism in 2025 gave mice 90 consecutive days of drinking water containing NMN (800 mg/kg). The results:
NAD⁺ levels in the liver, muscle, and brain of 18-month-old mice (approximately 60 years old in humans) returned to 82%–94% of those at 4 months of age;

mitochondrial membrane potential increased by 28%, and the inflammatory factor IL-6 decreased by 46%;
maximum running distance increased by 1.7 times, and hair density returned to the level of "middle-aged mice."
Similar results have been repeatedly reported in papers by Harvard Sinclair and Shinichiro Imai of the University of Washington, becoming almost standard data.

 

2. Human Clinical Trials: "Moderate" Effects but Clear Trends
To date, over 20 NMN powder human trials have been completed and published globally. The conclusions can be summarized in three sentences:
NAD⁺ blood concentrations can be increased 2–5-fold in a dose-dependent manner;
Functional indicators such as insulin sensitivity, the 6-minute walk test, and sleep quality have improved, but the sample sizes are small (mostly <100 participants) and the duration is short (≤12 weeks);
No hepatotoxicity or renal toxicity has been observed at ≤900 mg daily for two consecutive months, but long-term safety still needs to be monitored.

 

 

NMN, NMNH, or NADH: Which is the "true" NAD⁺ booster?

 

1. Biochemical Pathway: One "Highway," Two "National Highways"
Highway: NMN → NMNAT → NAD⁺ (One-step direct route, blood concentration increases within 30 minutes)
Auxiliary: NR → NMN → NAD⁺ (An additional phosphorylation step, slightly lower efficiency)
Reduction: NADH enters the bloodstream orally, directly increasing intracellular NADH. This then indirectly increases NAD⁺ via the "NADH → NAD⁺" redox balance, but the magnitude of the increase is limited. Its advantage is that there is more robust evidence for its antioxidant and anti-fatigue properties.
New Dark Horse: Reduced NMNH (nicotinamide mononucleotide) was first synthesized on a ton-scale by a domestic team in 2023. Animal studies have shown that it increases NAD⁺ 2–3 times that of NMN, but human data have yet to be published.

 

2. Bioavailability Measurement
In 2025, a randomized crossover trial in which 12 healthy volunteers took equal doses of NMN, NMNH, and NADH (500 mg) showed the following 24-hour AUC (area under the curve):
NMNH > NMN > NADH, with a ratio of approximately 3:1.5:1.
The incidence of side effects (flushing, stomach discomfort) was highest with NADH (33%) and lowest with NMNH (8%).

Thus, if the goal is to "rapidly and significantly increase NAD⁺," NMNH ≈ NMN > NR > NADH. If the focus is on "fatigue and antioxidant" benefits, NADH remains irreplaceable. Brands can choose between a "single ingredient" or "cocktail formulation" based on their product positioning.

 

How to ensure the safety of NAD⁺ raw materials?

 

1. Safety Red Lines: Solvent Residues and Genotoxic Impurities
There are two main routes for the industrialization of β-nicotinamide mononucleotide (NMN): the "chemical-enzymatic" method and the "holoenzymatic" method. The former is prone to introducing organic solvents (acetonitrile, dichloromethane) and heavy metals, while the latter has mild reaction conditions but high enzyme preparation costs. In 2024, the EU EFSA added "β-nicotinamide mononucleotide" to its Novel Food review list, requiring a full set of 90-day toxicology, genotoxicity, impurity profile, and stability data. This means that "small-scale" raw materials will be eliminated from the market.

 

2. Regulatory Updates: Domestic "Cosmetics First," Food "Waiting"

China's National Health Commission accepted NMN as a new food ingredient in 2023, but it has not yet passed technical review.

The National Medical Products Administration will include NMN in the "Catalogue of Cosmetic Ingredients" in 2024, allowing it to make "anti-wrinkle and moisturizing" claims.

 

The US FDA rejected NMN's NDI (Dietary Supplement) registration in 2022, and it is currently being sold as an "old product, old method."

Japan's Ministry of Health, Labor and Welfare approved NMN as a "food with functional claims" as early as 2020, making it a top choice for brands expanding overseas.

Sost Biotech - A One-Stop NAD⁺ Ingredient Supermarket

 

If you're looking for reliable, compliant, and affordable NAD⁺ raw material ingredients, be sure to save this article and forward it to your purchasing colleagues. With 15 years of experience in enzyme catalysis and fermentation processes,

Sost Biotech has established a comprehensive production line for NAD⁺, NMN, NMNH, and NADH:

1,000 square meters of GMP cleanroom space, with an annual production capacity of 20 tons;

Fully enzymatic process, zero residual solvents, and heavy metals <5 ppm;

 

Contact: info@sostherbusa.com